{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T07:24:02Z","timestamp":1758093842259,"version":"3.44.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstert.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.fertnstert.2022.10.024","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T15:20:07Z","timestamp":1671204007000},"page":"170-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["More follicle-stimulating hormone may not improve outcomes, but can it be counterproductive?"],"prefix":"10.1016","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5491-0913","authenticated-orcid":false,"given":"Molly M.","family":"Quinn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Paulson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2022.10.024_bib1","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/0002-9378(90)90790-E","article-title":"Factors affecting embryo implantation after human in\u00a0vitro fertilization: a hypothesis","volume":"163","author":"Paulson","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2022.10.024_bib2","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/humrep\/dey217","article-title":"Luteal phase anovulatory follicles result in the production of competent oocytes: intra-patient paired case-control study comparing follicular versus luteal phase stimulations in the same ovarian cycle","volume":"33","author":"Cimadomo","year":"2018","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.10.024_bib3","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(07)60360-2","article-title":"A mild treatment strategy for in-vitro fertilization: a randomized non-inferiority trial","volume":"369","author":"Heijnen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2022.10.024_bib4","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.fertnstert.2015.07.1151","article-title":"Gonadotropin dose is negatively correlated with live birth rate: analysis of more than 650,000 assisted reproductive technology cycles","volume":"104","author":"Baker","year":"2015","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2022.10.024_bib5","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1093\/humrep\/dex094","article-title":"High FSH dosing is associated with reduced live birth rate in fresh but not subsequent frozen embryo transfers","volume":"32","author":"Munch","year":"2017","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.10.024_bib6","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.fertnstert.2013.08.045","article-title":"Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in\u00a0vitro fertilization patients treated with recombinant follicle-stimulating hormone\/gonadotropin-releasing hormone antagonist in six trials","volume":"100","author":"Griesinger","year":"2013","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2022.10.024_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/09513590.2014.959919","article-title":"Do poor-responder patients benefit from increasing the daily gonadotropin dose during controlled ovarian hyperstimulation for IVF?","volume":"31","author":"Haas","year":"2015","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2022.10.024_bib8","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.fertnstert.2015.08.014","article-title":"450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial","volume":"104","author":"Lefebvre","year":"2015","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2022.10.024_bib9","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.fertnstert.2009.03.027","article-title":"What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders?","volume":"94","author":"Berkkanoglu","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2022.10.024_bib10","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/humrep\/del484","article-title":"Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial","volume":"22","author":"Baart","year":"2007","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.10.024_bib11","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1093\/humrep\/dem285","article-title":"The ISMAAR proposal on terminology for ovarian stimulation for IVF","volume":"22","author":"Nargund","year":"2007","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.10.024_bib12","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1210\/jc.2012-1738","article-title":"Moderate ovarian stimulation does not increase the incidence of human chromosomal abnormalities in in\u00a0vitro fertilization cycles","volume":"97","author":"Labarta","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2022.10.024_bib13","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/humrep\/der106","article-title":"Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles","volume":"26","author":"Sunkara","year":"2011","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.10.024_bib14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1055\/s-2008-1042958","article-title":"Oocyte quality in adult polycystic ovary syndrome","volume":"26","author":"Patel","year":"2008","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.fertnstert.2022.10.024_bib15","first-page":"1","article-title":"Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in\u00a0vitro fertilization plus intracytoplasmic sperm injection (IVF\/ICSI)","volume":"2","author":"Lensen","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.fertnstert.2022.10.024_bib16","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/humrep\/dex318","article-title":"Individualized versus standard FSH dosing in women starting IVF\/ICSI: an RCT. Part 1: the predicted poor responder","volume":"32","author":"Van TIlborg","year":"2017","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2022.10.024_bib17","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/humrep\/deac113","article-title":"Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial","volume":"37","author":"Liu","year":"2022","journal-title":"Hum Reprod"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028222019744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028222019744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T08:37:11Z","timestamp":1758011831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0015028222019744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0015028222019744"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2022.10.024","relation":{},"ISSN":["0015-0282"],"issn-type":[{"type":"print","value":"0015-0282"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"More follicle-stimulating hormone may not improve outcomes, but can it be counterproductive?","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2022.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92022 American Society for Reproductive Medicine, Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}